Health Disparities in Screening, Diagnosis, and Treatment of Hepatocellular Carcinoma
Averill Guo, Sydney Pomenti, Julia Wattacheril – 15 February 2022
At Diagnosis of Hepatocellular Carcinoma, African Americans With Hepatitis C Have Better Liver Function Than Other Patients
Adam C. Winters, Julie C. Sung, Brooke Wyatt, Deeva Berera, Thomas D. Schiano, Myron E. Schwartz, Ponni V. Perumalswami, Andrea D. Branch – 15 February 2022
Hepatology Highlights
13 February 2022
Seeking Editor for Clinical Liver Disease
13 February 2022
Masthead
13 February 2022
Single MHC‐I Expression Promotes Virus‐Induced Liver Immunopathology
Haifeng C. Xu, Jun Huang, Aleksandra A. Pandyra, Piyush Pandey, Ruifeng Wang, Zeli Zhang, Yuan Zhuang, Christoph G.W. Gertzen, Carsten Münk, Diran Herebian, Arndt Borkhardt, Mike Recher, Holger Gohlke, Irene Esposito, Martin Oberbarnscheidt, Dieter Häussinger, Karl S. Lang, Philipp A.
Cover Image
13 February 2022
Instructions to Authors
13 February 2022
Table of contents
13 February 2022
Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?
Marlyn J. Mayo – 12 February 2022 – Treatment of primary biliary cholangitis (PBC) with ursodeoxycholic acid (UDCA) is not always sufficient to prevent progression to hepatic decompensation and/or need for liver transplant. Adjuvant therapy with obeticholic acid may provide additional biochemical improvements in some patients, but it is not well‐tolerated by patients with significant itch or advanced cirrhosis. Thus, new and creative approaches to treating patients with PBC are important to identify.